September 1, 2026 · Phase 3 readout
UCBJY Phase 3 readout: a neutral outcome, +1.0%
+1.0%UCB (UCBJY) →
On September 1, 2026, fenfluramine — UCB (Dravet Syndrome) reached its Phase 3 readout. The result was a neutral outcome, and the stock moved +1.0% in the window around the event.
The move
$124.96
1d before
$126.22
Event day
$127.69
1d after
$122.38
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.0% expected); the stock actually moved +1.0%. Model confidence at the time: 95%.
See the full scored track recordPre-catalyst setup
-2.5%
30-day run-up
2675%
30-day volatility
1.7×
volume spike